Cialis shop

Analysis of these data revealed that the overall MI incidence rate was similar in placebo-treated (0.95/100 PY) and sildenafil citrate-treated patients (0.85/100 PY; P = 0.801).

For the open-label studies, analysis of data from patients representing 10,859 PY of sildenafil citrate exposure demonstrated an MI incidence rate of 0.53/100 PY. The overall MI rate for double-blind and open-label sildenafil citrate-treated patients was 0.58/100 PY. Similar rates have been reported in a number of epidemiologic studies (44).

The database also contains (as of September 30, 2001) reports of 5 deaths (cialis shop from all causes) among double-blind placebo-treated patients and 9 deaths among sildenafil citrate-treated patients. This corresponds to all-cause mortality rates of 0.53/100 PY and 0.55/100 PY, respectively (P = 0.945).

The overall (double-blind and open-label) mortality rate among sildenafil citrate-treated patients was 0.37/100 PY, which is lower than that (0.66/100 PY) calculated for men aged 40 to 64 years in the US for 1999.

These results clearly show that the incidences of MI and all-cause mortality among patients who received double-blind and/or open-label sildenafil citrate treatment are similar to those observed among patients who received placebo, or in men in the same age cohort of the general population (43). Carson III (45) reported that the incidence of adverse cardiovascular events in patients taking sildenafil does not differ from that for the general population.

Cardiac electrophysiological effects of sildenafil citrate. In the past few years, the cardiac electrophysiological effects of

sildenafil

Geelen and colleagues (46) demonstrated that sildenafil citrate induces a dose-dependent block of the rapid component of the delayed rectifier potassium current ( I Kr ). They also reported that sildenafil citrate can have an action similar to that of class III antiarrhythmic drugs (46). These effects are observed at concentrations that may be found in conditions of impaired drug elimination such as renal or hepatic insufficiency, during co-administration of another CYP3A4 inhibitor, or after drug overdose (11).

Prolonged cardiac repolarization caused by sildenafil citrate could result in malignant ventricular arrhythmias and lead to sudden cardiac death in some of these patients (11). Swissa and colleagues (47) demonstrated that a combination of sildenafil citrate and a nitric oxide donor increases ventricular tachyarrhythmia/VF vulnerability in the normal right ventricle of swine. Although many reports have demonstrated the arrhythmogenic effects of sildenafil citrate, some studies have reported otherwise.

Vardi and colleagues (48) showed that sildenafil citrate does not alter the hemodynamic responses to exercise or change the incidence of ventricular arrhythmias in men with cardiovascular disease and ED. Chiang and colleagues (49) found that sildenafil citrate at concentrations up to 30 µM has no significant effect on either the rapid ( I Kr ) or the slow ( I Ks ) components of the delayed rectifier potassium currents in guinea pig ventricular myocytes. They also found that sildenafil citrate dose-dependently blocks L-type Ca 2+ currents ( I Ca,L ), but has no effect on persistent Na + currents.

They concluded that sildenafil citrate does not prolong cardiac repolarization.

Instead, in supra-therapeutic concentrations, it accelerates cardiac repolarization, presumably via its blocking effect on I Ca,L (49). Recent studies have also demonstrated that oral administration of 50 mg sildenafil citrate does not affect QT dynamic properties (50).

Furthermore, Nagy and colleagues (51) recently reported that sildenafil citrate reduces arrhythmia severity during ischemia 24 h after oral administration in dogs.

Ischemic preconditioning results in powerful cardioprotective effects (52). Repeated brief episodes of ischemia initiate a cascade of intracellular signaling events which help prevent future myocardial infraction and stunning (52).

After initial observation, this phenomenon, termed "myocardial preconditioning", was studied intensively to try to understand its cellular mechanisms and apply this knowledge towards protection of the human heart from ischemic heart disease. Current data suggest that sildenafil citrate has a preconditioning-like cardioprotective effect in the rabbit, rat and mouse heart (53).

Das and colleagues (54) reported that sildenafil citrate at a much lower dose (0.05 mg/kg) provides significant cardioprotection in isolated perfused rat hearts following global ischemic-reperfusion. They observed an improved post-ischemic recovery of ventricular function, a reduction in the incidence of VF, and a decrease in MI. At higher doses, sildenafil caused a significant increase in the incidence of VF, while at very low doses it had no effect on

cardiac

However, a study by Reffelmann and Kloner (55) demonstrated otherwise. In their report, they did not find a decrease in myocardial necrosis following ischemia-reperfusion in a rabbit model.

The reason for these negative results was not clear.

The only noticeable difference in the experimental procedure was a considerably longer drug infusion time ( 5 min) in the study by Reffelmann and Kloner (55) as compared to that used by Ockaili and colleagues (56) ( 1 min), which could potentially affect the hemodynamic response prior to ischemia. Signaling mechanisms in sildenafil-induced cardioprotection.

Although sildenafil citrate has been shown to have a powerful preconditioning-like cardioprotective effects in animal models of ischemia-reperfusion injury, the precise cellular mechanism underlying these effects remains unclear. The sildenafil citrate-induced cardioprotective effect against ischemia-reperfusion injury is dependent upon the opening of mitochondrial ATP-sensitive potassium channels (mitoK ATP channels) in rabbits (56).

It has been proposed that the vasodilatory action of sildenafil citrate could potentially cause the release of endogenous mediators of preconditioning, such as adenosine or bradykinin from endothelial cells, which may trigger a signaling cascade (through the action of kinases) and the release of nitric oxide (56).

Generation of nitric oxide could potentially activate guanylate cyclase, resulting in an enhanced formation of cGMP (57).

cGMP may activate protein kinase G, which could then open mitoK ATP channels, resulting in both acute and delayed cardioprotective effects (58).

Mitochondria are known to play an essential role in cell survival via ATP synthesis and maintenance of Ca 2+ homeostasis (59). Opening mitoK ATP channels partially compensates the membrane potential, which enables additional protons to be pumped out to form an H + electrochemical gradient to drive both ATP synthesis and Ca 2+ transport.

Recently, Das and colleagues (60) reported that protein kinase C also plays an essential role in sildenafil-induced cardioprotection in rabbits. We conclude that, in view of the increasing incidence of sudden cardiac death in ED patients treated with sildenafil citrate, it is essential to understand how this drug affects the entire cardiovascular system, especially the heart.

According to extensive data available to date, sildenafil citrate has been shown to pose minimal cardiovascular risks to healthy people taking this drug. Some precautions, however, are needed for patients with cardiovascular disease. Further clinical and basic investigation on the cardiovascular effects of sildenafil citrate is needed to assure proper treatment of ED in patients with cardiovascular disease.

Chew KK, Earle CM, Stuckey BG, Jamrozik K & Keogh EJ (2000). Erectile dysfunction in general medicine practice: prevalence and clinical correlates.

International Journal of Impotence Research , 12: 41-45. Sexual dysfunction in the United States: prevalence and predictors. Journal of the American Medical Association , 281: 537-544. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ & McKinlay JB (1994). Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y & Braf Z (1997).

Does severity of ischemic coronary disease correlate with erectile function? International cialis shop Journal of Impotence Research , 9: 123-126. Israilov S, Baniel J, Shmueli J, Niv E, Engelstein D, Segenreich E & Livne PM (2004). Treatment program for erectile dysfunction in patients with cardiovascular diseases. Khan MA, Ledda A, Mikhailidis DP, Rosano G, Vale J, Vickers M & Consensus Writing Committee (2002).

Second Consensus Conference on Cardiovascular Risk Factors and Erectile Dysfunction. Erectile dysfunction and sildenafil citrate and cardiologists. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD & Wicker PA (1998). Oral sildenafil in the treatment of erectile dysfunction.

Shakir SA, Wilton LV, Boshier A, Layton D & Heeley E (2001). Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel.

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

Acute myocardial infarction after the use of sildenafil. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. International Journal of Clinical Practice , 57: 597-600.

Manfroi WC, Caramori PR, Zago AJ, Melchior R, Zen V, Accordi M, Gutierres D & Noer C (2003).

Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. Cheitlin MD, Hutter Jr AM, Brindis RG, Ganz P, Kaul S, Russell Jr RO & Zusman RM (1999). Use of sildenafil (Viagra) in patients with cardiovascular disease.

Cheitlin MD, Hutter Jr AM, Brindis RG, Ganz P, Kaul S, Russell Jr RO & Zusman RM (1999). Use of sildenafil (Viagra) in patients with cardiovascular disease.

American College cialis shop of Cardiology/American Heart Association.

Journal of the American College of Cardiology , 33: 273-282.

Effect of oral milrinone on mortality in severe chronic heart failure. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S & de Breyne B (1994). Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. European Journal of Clinical Pharmacology , 46: 191-196.

Corbin J, Rannels S, Neal D, Chang P, Grimes K, Beasley A & Francis S (2003).

Sildenafil citrate does not affect cardiac contractility in human or dog heart.

Current Medical Research and Opinion , 19: 747-752. Herrmann HC, Chang G, Klugherz BD & Mahoney PD (2000).

Hemodynamic effects of sildenafil in men with severe coronary artery disease. Rajfer J, Aronson WJ, Bush PA, Dorey FJ & cialis shop Ignarro LJ (1992).

Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. Sebkhi A, Strange JW, Phillips SC, Wharton J & Wilkins MR (2003). Phosphodiesterase type 5 as a target for cialis shop the treatment of hypoxia-induced pulmonary hypertension.

Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R & Block LH (2003). Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M & Sybrecht GW (2001). Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.

Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Chattipakorn N, Fotuhi PC, Zheng X & Ideker RE (2000).

Left ventricular apex ablation decreases the upper limit of vulnerability.

Chattipakorn N, Fotuhi PC, Sreenan CM, White JB & Ideker RE (2000). Pacing after shocks stronger than the upper limit of vulnerability: impact on fibrillation induction.

Influence of postshock epicardial activation patterns on initiation of ventricular fibrillation by upper limit of vulnerability shocks. Chattipakorn N, Banville I, Gray RA & Ideker RE (2001).

Mechanism of ventricular defibrillation for near-defibrillation threshold shocks: a whole-heart optical mapping study in swine.

Chattipakorn N, Fotuhi PC, Chattipakorn SC & Ideker RE (2003). Three-dimensional mapping of earliest activation after near-threshold ventricular defibrillation shocks. Journal of Cardiovascular Electrophysiology , 14: 65-69. Pediatric Clinics of North America , 51: 1211-1221.

Pacing following shocks stronger than the defibrillation threshold: impact on defibrillation outcome.

Journal of Cardiovascular Electrophysiology , 11: 1022-1028.

Prediction of defibrillation outcome by epicardial activation patterns following shocks near the defibrillation threshold. Journal of Cardiovascular Electrophysiology , 11: 1014-1021. Chattipakorn N, Banville I, Gray RA & Ideker RE (2004).